title: Case study for a vaccine against leishmaniasis.
abstract: Leishmaniasis in many ways offers a unique vaccine case study. Two reasons for this are that leishmaniasis is a disease complex caused by several different species of parasite that are highly related, thus raising the possibility of developing a single vaccine to protect against multiple diseases. Another reason is the demonstration that a leishmaniasis vaccine may be used therapeutically as well as prophylactically. Although there is no registered human leishmaniasis vaccine today, immunization approaches using live or killed organisms, as well as defined vaccine candidates, have demonstrated at least some degree of efficacy in humans to prevent and to treat some forms of leishmaniasis, and there is a vigorous pipeline of candidates in development. Current approaches include using individual or combined antigens of the parasite or of salivary gland extract of the parasites' insect vector, administered with or without formulation in adjuvant. Animal data obtained with several vaccine candidates are promising and some have been or will be entered into clinical testing in the near future. There is sufficient scientific and epidemiological justification to continue to invest in the development of vaccines against leishmaniasis.
authors.affiliation: Drugs for Neglected Disease initiative (DNDi) 15, Chemin Louis-Dunant, 1202 Geneva, Switzerland.
authors.forename: Jorge
authors.initials: J
authors.lastname: Alvar
authors.forename: Simon L
authors.initials: SL
authors.lastname: Croft
authors.forename: Paul
authors.initials: P
authors.lastname: Kaye
authors.forename: Ali
authors.initials: A
authors.lastname: Khamesipour
authors.forename: Shyam
authors.initials: S
authors.lastname: Sundar
authors.forename: Steven G
authors.initials: SG
authors.lastname: Reed
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D035843:Biomedical Research / Q000639:trends*; D002986:Clinical Trials as Topic; D006801:Humans; D007896:Leishmaniasis / Q000517:prevention & control*; D054332:Leishmaniasis Vaccines / Q000627:therapeutic use*; D014613:Vaccines, Attenuated / Q000627:therapeutic use; D015164:Vaccines, Inactivated / Q000627:therapeutic use; D022223:Vaccines, Subunit / Q000627:therapeutic use
chemical_list: D000953:Antigens, Protozoan; D054332:Leishmaniasis Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D022223:Vaccines, Subunit